Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that ...

Though it’s been used off-label for more than three decades to treat cerebrotendinous xanthomatosis, Mirum Pharmaceuticals Inc.’s chenodiol gained an official U.S. FDA nod Feb. 21 as the first drug ...

Aptamers are single-stranded DNA or RNA molecules with unique 3D structures that allow for specific binding to a wide variety of ions and molecules. Due to their unique properties, aptamers have been ...

EG 427 SAS has closed a €27 million (US$28.3 million) series B round, which will fund it to completion of the first clinical ...

A new version of Evo, the AI developed at the Arc Institute that can be used to design genomes as long as that of a bacterium, has been retrained with the DNA sequences of three domains of life – ...

The lung and thrombosis may play a key role in cancer and metastasis progression, according to a collaborative study led by ...

The first patenting from Theta Neurotech Inc. sees the company’s co-founders describe their development of a wearable earpiece that uses an electroencephalography technology and machine learning ...

Artificial intelligence (AI) technology developer Genesis Therapeutics Inc. has brought in another larger partner to go on a search for the right therapeutic small molecules. The company is getting an ...

The longstanding ambition of developing an inhaled gene therapy for cystic fibrosis has taken a step forward, with the start of a phase I/II trial of a product using a novel pseudotyped viral vector ...

Up to 50% of glaucoma cases have a genetic component, a factor which could significantly change the screening recommendations and monitoring of patients – if they know their risk. Seonix Pty. Ltd. has ...

The latest patenting from Canan Dagdeviren seeks protection for their wearable, conformable ultrasound breast patch that ...

Researchers from Tianjin University have published data regarding development and preclinical characterization of a new anti-PD-L1/CD40 bispecific antibody (BsAb), BA-4415, designed to activate CD40 ...